ClinicalTrials.gg
RecruitingNCT07434778IMPROVE-PIUUpdated Aug 5, 2026

Group-based IMPROVE Therapy for Problematic Internet Use in University Students

An interventional study of IMPROVE Program and Digital Psychoeducation Newsletters in Problematic Internet Use, sponsored by Sir Run Run Shaw Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Sir Run Run Shaw Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Motor Activity with a site in China — 41 open to participants now, 49 under way, 1 of them phase 3. Motor Activity · China.

Planned enrollment
12th of 113
600 · median 113
Started
2026
with 21 others
No phase
105 of 132
29 open now
Primary completion
2027-06
later than 40 of 48 live
Registered
105th of 132
by date

Among the 132 studies in Motor Activity with a site in China, this one is the 12th largest by planned enrollment of the 113 interventional ones that give a count, is one of 22 that started in 2026, is one of 105 with no phase, reaches primary completion later than 40 of the 48 other live ones, and was the 105th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

41 of the 132 studies in Motor Activity with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Motor Activity with a site in China, or all of them as a file.
02

Study summary

Problematic internet use (PIU) is a growing behavioral health concern among university students. This study aims to evaluate the effectiveness and psychological mechanisms of "IMPROVE," a manualized, multimodal group-based psychotherapy. The IMPROVE program integrates cognitive-behavioral strategies with motivational elements, mindfulness training, and socially interactive exercise. In this randomized controlled trial, 600 university students with moderate to severe PIU will be randomized to either the 8-week IMPROVE intervention or an enhanced waitlist control group. The primary outcome is the change in PIU severity, assessed by the Internet Addiction Test (IAT) score, from baseline to the post-intervention endpoint (8 weeks).

Read the detailed description

Problematic internet use (PIU) has emerged as a prevalent and clinically significant behavioral health problem among university students, characterized by impaired control over online behaviors and associated psychological distress, functional impairment, and academic difficulties. It is increasingly conceptualized as a spectrum of heterogeneous behaviors (e.g., gaming, social media use, short-form video consumption) rather than a single homogeneous entity.

Although a growing body of research has examined interventions for PIU, the current evidence base remains limited by several methodological shortcomings, including small sample sizes , short intervention durations, insufficient follow-up, insufficient consideration of the heterogeneity of PIU, and a lack of theory-driven investigation into psychological mechanisms of change. Moreover, many existing interventions focus on single components (e.g., cognitive-behavioral techniques alone), while neglecting the multidimensional nature of PIU, which involves complex interactions between cognitive biases, emotion dysregulation, and anhedonia.

To address these gaps, this prospective, single-blind, parallel-group randomized controlled trial evaluates the efficacy, durability, and potential mechanisms of action of a manualized, group-based intervention-IMPROVE therapy-for treatment-seeking university students with PIU. IMPROVE therapy is designed as an integrative program that combines cognitive-behavioral strategies with motivational elements, mindfulness training, and socially interactive exercise, targeting core psychological processes implicated in the development and maintenance of PIU.

Eligible participants will be randomized in a 1:1 ratio to the IMPROVE intervention group or the enhanced waitlist control group using a centralized computer-generated allocation sequence. Participants in the IMPROVE group receive an 8-week structured group therapy consisting of one 120-minute session per week . Outcome assessments are conducted at baseline (T0), mid-intervention (Week 4, T1), post-intervention (Week 8, T2), and at follow-up time points of 1 month (T3), 3 months (T4), 6 months (T5), and 12 months (T6) after completion of the intervention.

The primary objective of the trial is to determine whether IMPROVE therapy leads to a greater reduction in PIU severity compared with the enhanced waitlist control at the end of the intervention. Accordingly, the primary outcome is PIU severity measured by the Internet Addiction Test (IAT), operationalized as the between-group difference in change in IAT total score from baseline (T0) to the post-intervention endpoint (T2).

The secondary objectives are to evaluate (1) the maintenance and durability of treatment effects across short-, medium-, and long-term follow-up periods, and (2) additional clinically relevant outcomes related to PIU. Secondary outcomes therefore include IAT scores at follow-up time points (T3-T6), rates of clinical remission defined by a prespecified IAT threshold, changes in associated psychological symptoms and functional impairment, and indicators of feasibility, adherence, and acceptability of the group-based intervention.

A core objective of this trial is to elucidate how the intervention exerts its effects. Guided by the I-PACE model, candidate psychological mediators will be assessed at baseline (T0), mid-intervention (T1), post-intervention (T2), and the 3-month follow-up (T4). Longitudinal mediation analyses will examine whether changes in maladaptive internet-related cognitions, emotion regulation difficulties, self-efficacy, anhedonia, perceived stress, mind wandering, and resilience statistically account for subsequent changes in PIU severity. Among participants reporting recent gaming, gaming-related maladaptive cognitions assessed using the C-RIGCS will also be examined.

A subset of participants of the IMPROVE intervention group will voluntarily undergo neuroimaging (fMRI) and blood sampling at T0 and T2 to explore the neurobiological correlates of therapeutic change.

Outcome assessors and data analysts will be blinded to treatment allocation to minimize assessment and analytic bias.

03

Conditions studied

  • Problematic Internet Use

Browse trials for

Keywords

  • problematic internet use
  • digital addiction
  • group psychotherapy
  • mindfulness
  • cognitive-behavioral therapy
  • exercise
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. be university students aged between 18 and 30 years;
  2. report subjective suffering regarding their own internet use and score 50 or above on the Internet Addiction Test (IAT), indicating at least a moderate level of PIU;
  3. own a personal smartphone or other electronic communication device to ensure accessibility to digital intervention components;
  4. provide written prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. a self-reported history of substance use (excluding tobacco and alcohol) within the past 12 months;
  2. current or previous participation in any form of psychotherapy for PIU;
  3. the presence of severe physical or neurological conditions (e.g., organic brain diseases, history of traumatic brain injury, or coma);
  4. a self-reported history of diagnosed psychiatric disorders (e.g., schizophrenia, bipolar disorder).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    IMPROVE Intervention Group

    Participants receive IMPROVE therapy delivered in groups over 8 weeks, with 120 minutes per week (8 sessions total). The program integrates cognitive-behavioral strategies with motivational elements, mindfulness training, and socially interactive exercise. Sessions will be delivered by trained therapists using a standardized intervention manual, with regular weekly supervision to support consistency of intervention delivery.

    Behavioral: IMPROVE Program

  • Other
    Enhanced Waitlist Control (EWC) Group

    Participants will receive one standardized digital newsletter per week via WeChat during the initial 8-week intervention period (T0-T2). They will then remain on the waitlist until completion of the 3-month follow-up assessment (T4), after which they will be offered the full 8-week IMPROVE intervention.

    Behavioral: Digital Psychoeducation Newsletters

Interventions

  • BehavioralIMPROVE Program

    A manualized, group-based, multimodal integrative psychotherapy. It integrates CBT-informed strategies, Mindfulness-Based Interventions, and Socially Interactive Exercise. Delivered over 8 weekly sessions (120 minutes each). Groups consist of 10-15 participants

  • BehavioralDigital Psychoeducation Newsletters

    Weekly newsletters pushed via WeChat containing psychoeducation on consequences of internet use and general advice for reducing screen time.

06

What researchers measure

Primary outcomes

  1. Change in Problematic Internet Use Severity (IAT Score)

    Assessed using the Internet Addiction Test (IAT). Scores range from 20 to 100, with higher scores indicating greater severity. The primary endpoint is the change from baseline to post-intervention

    Time frame: Baseline (T0) and Post-intervention (Week 8, T2)

Secondary outcomes

  1. Long-term Change in PIU Severity (IAT)

    Assessing the maintenance of intervention effects using the Internet Addiction Test (IAT) scores during the follow-up phase.

    Time frame: Month 1 (T3), Month 3 (T4), Month 6 (T5), and Month 12 (T6) Follow-up

  2. Participant Satisfaction and Acceptability

    Participant satisfaction and acceptability will be assessed at postintervention using an adapted eight-item questionnaire based on the Client Satisfaction Questionnaire, supplemented by study-specific closed-ended items assessing overall programme quality, perceived helpfulness, needs fulfilment, willingness to recommend or participate again, satisfaction with therapist guidance, the helpfulness of individual sessions and intervention components, session length, programme duration, between-session practice burden, and group atmosphere. Item-level response distributions will be summarized descriptively.

    Time frame: Post-intervention at Week 8 (T2)

  3. Smartphone Addiction Risk (SAS-SV)

    Assessed using the Smartphone Addiction Scale-Short Version (SAS-SV). Scores range from 10 to 60, with higher scores indicating higher risk of smartphone addiction.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  4. Internet-use Disorder severity based on ICD-11 criteria (ACSID-11)

    Assessed using the Assessment of Criteria for Specific Internet-use Disorders (ACSID-11). Frequency scores of four core ICD-11 diagnostic features (impaired control, increasing priority, continuation despite negative consequences, and functional impairment) will be evaluated. Scores range from 0 to 33, with higher scores indicating more severe addiction.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  5. Internet Usage Duration

    Self-reported daily usage hours. Prior to trial implementation, objective smartphone use time was removed from the secondary outcomes due to limited comparability across smartphone brands and operating systems.

    Time frame: Baseline (T0), Week 4 (T1), Week 8 (T2), Month 1 (T3), Month 3 (T4), Month 6 (T5), and Month 12 (T6) Follow-up.

  6. Craving Intensity (QSU-Brief)

    Assessed using a modified Questionnaire on Smoking Urges-Brief (QSU-Brief) adapted for internet use. Scores range from 10 to 70, with higher scores indicating more severe craving.

    Time frame: Baseline (T0), Week 4 (T1), Week 8 (T2), Month 1 (T3), Month 3 (T4), Month 6 (T5), and Month 12 (T6) Follow-up

  7. Functional Impairment (BNCS Score)

    Assessed using the adapted Brief Negative Consequence Scale (BNCS). Evaluates negative consequences across six domains (occupational, academic, interpersonal, etc.) on a 4-point scale. Scores range from 0 to 18, with higher scores suggesting more functional impairment.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  8. Depressive Symptoms (PHQ-9 Score)

    Assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depression.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  9. Anxiety Symptoms (GAD-7 Score)

    Assessed using the Generalized Anxiety Disorder-7 (GAD-7). Scores range from 0 to 21, with higher scores indicating more severe anxiety.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  10. Insomnia Severity (ISI Score)

    Assessed using the Insomnia Severity Index (ISI). Scores range from 0 to 28, with higher scores indicating more severe insomnia.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  11. ADHD Symptoms (ASRS-v1.1 Score)

    Assessed using the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist to screen for attention-deficit/hyperactivity disorder symptoms.The total score ranges from 0 to 72. Higher scores indicate greater ADHD symptom severity.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  12. Mental Well-being (WHO-5 Index)

    Assessed using the WHO-Five Well-Being Index. A 5-item measure of current mental well-being. Each item is scored from 0 to 5. The raw total score ranges from 0 to 25. Higher scores indicate better mental well-being.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  13. Subjective Quality of Life (QOL-VAS)

    Assessed using a single-item Quality of Life Visual Analog Scale (0-100), where 100 represents the best imaginable quality of life.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  14. Physical Activity Level (IPAQ-SF)

    Assessed using the International Physical Activity Questionnaire - Short Form (IPAQ-SF). Measures frequency and duration of physical activity. Physical activity is expressed as metabolic equivalent task minutes per week (MET-minutes/week), derived from walking, moderate-intensity, and vigorous-intensity activities. Higher values indicate greater levels of physical activity. There is no fixed upper limit.

    Time frame: Baseline (T0), Post-intervention at Week 8 (T2), Month 3 (T4), and Month 12 (T6) Follow-up

  15. Maladaptive Cognitions related to internet use (CAMCS)

    Assessed using the Chinese Adolescents Maladaptive Cognitions Scale (CAMCS). Measures dimensions such as social comfort, distraction, and self-realization. The total score ranges from 0 to 48. Higher scores indicate greater levels of maladaptive cognitions.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  16. Emotion Regulation Difficulties (DERS Score)

    Assessed using the Difficulties in Emotion Regulation Scale (DERS-16).The total score ranges from 16 to 80. Higher scores indicate greater problems with emotion regulation.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  17. General Self-Efficacy (GSES Score)

    Assessed using the General Self-Efficacy Scale (GSES). Measures perceived ability to cope with challenges. Items are rated on a 4-point Likert scale (1-4). The total score ranges from 10 to 40. Higher scores indicate greater perceived self-efficacy.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  18. Anhedonia (ASA-C Score)

    Assessed using the Anhedonia Scale for Adolescents-Chinese version (ASA-C) to evaluate reward processing and motivation. The total score ranges from 0 to 42. Higher scores indicate worse anhedonia.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  19. Perceived Stress (PSS-10 Score)

    Assessed using the Perceived Stress Scale (PSS-10). Measures the degree to which life situations are appraised as stressful. Total scores range from 0 to 40, with higher scores suggesting higher perceived stress.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  20. Mind Wandering (MWQ Score)

    Assessed using the Mind Wandering Questionnaire (MWQ). Measures the frequency of task-unrelated thoughts. Scores range from 5 to 30, with higher scores indicating more frequent mind wandering.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  21. Resilience (CD-RISC-10 Score)

    Assessed using the 10-item Connor-Davidson Resilience Scale (CD-RISC). Measures stress coping ability. Scores range from 0 to 40, with higher scores suggesting better resilience.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  22. Internet gaming disorder severity (IGDS9-SF)

    Gamers were additionally assessed with IGDS9-SF. Measure the severity of IGD, the only internet-related behavioral addictions that get recognized in DSM-5 and ICD-11. Scores range from 9 to 45, with higher scores suggesting more severe internet gaming disorder.

    Time frame: Baseline (T0), Week 4 (T1), Week 8 (T2), Month 1 (T3), Month 3 (T4), Month 6 (T5), and Month 12 (T6) Follow-up for gamers only.

  23. Current craving intensity (VAS)

    Assessed by a single-item Visual Analogue Scale (VAS, 0-100) for current craving intensity. Higher scores indicate more severe craving.

    Time frame: Baseline (T0), Week 4 (T1), Week 8 (T2), Month 1 (T3), Month 3 (T4), Month 6 (T5), and Month 12 (T6) Follow-up

  24. Maladaptive Cognitions related to gaming (C-RIGCS)

    For gamers, The Chinese version of Revised Internet Gaming Cognition Scale (C-RIGCS) were also assessed. Scores range from 0 to 60, with higher scores suggesting more severe maladaptive cognitions related to gaming.

    Time frame: Baseline (T0), Mid-intervention at Week 4 (T1), Post-intervention at Week 8 (T2), and Month 3 Follow-up (T4)

  25. Clinical Remission of Problematic Internet Use

    Clinical remission is defined as an Internet Addiction Test total score below 50. Between-group comparisons will be conducted through the 3-month follow-up assessment (T4). Outcomes at T5 and T6 will be evaluated descriptively because participants in the enhanced waitlist control group will be offered the IMPROVE intervention after T4.

    Time frame: Postintervention at Week 8 (T2), Month 1 (T3), Month 3 (T4), Month 6 (T5), and Month 12 (T6)

Other outcomes

  1. Collection of neuroimaging data for exploratory analyses

    Structural and functional MRI data will be acquired in a voluntary substudy for exploratory, hypothesis-generating analyses. Imaging-derived metrics (e.g., regional brain measures, task-related activation, or connectivity indices) will be determined based on prespecified analytic plans developed prior to data analysis. Analyses will be restricted to consenting participants assigned to the IMPROVE intervention group and will examine within-participant changes in neuroimaging measures from T0 to T2 and their associations with clinical improvement.

    Time frame: Baseline (T0) and Post-intervention at Week 8 (T2)

  2. Collection of peripheral blood samples for exploratory biomarker analyses

    Peripheral blood samples will be collected for future exploratory analyses of stress-related and inflammatory biomarkers. Analyses will be restricted to consenting participants assigned to the IMPROVE intervention group and will examine within-participant changes in peripheral biological measures from T0 to T2 and their associations with clinical improvement.

    Time frame: Baseline (T0) and Post-intervention at Week 8 (T2)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data underlying the results reported in the primary and secondary trial publications, together with a data dictionary, will be made available upon reasonable request. Data will be available beginning after publication of the primary trial results and for 5 years. Requests must include a scientifically sound research proposal and statistical analysis plan and will be reviewed by the principal investigator and study team. Access will be subject to participant consent, applicable ethical and data-protection requirements, and execution of a data-use agreement. Approved data will be provided only for the analyses specified in the accepted proposal.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Beginning immediately after publication of the primary trial results and ending 5 years thereafter.

Access criteria: Researchers seeking access should submit a methodologically sound research proposal and statistical analysis plan to the principal investigator. Requests will be evaluated on the basis of scientific merit, feasibility, consistency with participant consent, and compliance with applicable ethical and data-protection requirements. Approved requesters will be required to sign a data-use agreement, and the data may be used only for the analyses specified in the approved proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 15 months is below that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartActual
Mar 17, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07434778
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 17, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Yanhui Liao, PhD
Contact
liaoyanhui@zju.edu.cn
+86 18814898844

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion